HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Becton, Dickinson Has First EUA In US For Smartphone-Linked Rapid Antigen Test

Researchers Recommend Wider OTC Distribution Of Rapid Antigen Tests

Executive Summary

BD has EUA for Veritor At-Home COVID-19 rapid antigen test using smartphone vision technology to interpret and digitally display results. Researchers at biotech firms and medical schools measure advantages of at-home use of rapid antigen tests over quantitative real-time polymerase chain reaction tests.

You may also be interested in...



US FDA Targets Making More COVID-19 Tests Available OTC With EUA Template Changes

Agency changes two of its emergency use authorization templates “to support authorization of more COVID-19 tests” for OTC use and to offer “flexible study recommendations.”

OTC COVID-19 Tests Have Abbott Seeing Continuing Demand For At-Home Diagnostics

“We see this is a as a significant opportunity, and quite frankly, a trend that's been happening overseas and is kind of now happening here in the US,” says Abbott Labs CEO Robert Ford.

Abbott, BD, Quidel OTC COVID-19 Tests Granted Emergency Use Authorization In US

FDA grants emergency use authorization to OTC COVID-19 testing products as it targets allowing workplaces, schools and communities to access tools needed to screen for the virus rapidly and accurately.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

RS151707

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel